Results 171 to 180 of about 1,628,316 (351)

Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To assess the value of serum type I interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial. Methods A retrospective, longitudinal lcSSc cohort was identified within a national, multicenter observational ...
Stefano Di Donato, Rebecca Ross, Ranjitha Karanth, Vishal Kakkar, Enrico De Lorenzis, Lesley‐Anne Bissell, Kristina Clark, Philip Yee, Christopher P. Denton, Francesco Del Galdo   +9 more
wiley   +1 more source

Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case‐specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options.
Thuong Trinh‐Minh, Cuong Tran‐Manh, Andrea‐Hermina Györfi, Nicholas Dickel, Christoph Liebel, Xiang Zhou, Jiucun Wang, Meik Kunz, Helena Arozenius, Lars Pettersson, Sam Lindgren, Christina Wenglén, Jörg H. W. Distler   +12 more
wiley   +1 more source

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

Arthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Effect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

Arthritis &Rheumatology, Accepted Article.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose ...
Brad H. Rovin, Clarissa Cassol, Samir V. Parikh, Amit Saxena, Neil Solomons, Vanessa Birardi, Ernie Yap, Clint W. Abner, David R.W. Jayne, Robert B. Huizinga   +9 more
wiley   +1 more source

Activin A‐activated ALK4 induces pathogenic Th17 involved endothelial–mesenchymal transition in systemic lupus erythematosus‐associated pulmonary arterial hypertension

Arthritis &Rheumatology, Accepted Article.
Objective Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE, has not been clarified.
Shuliang Jing, Junyan Qian, Hongjie Ying, Pei Mao, Mingxin Yao, Zhihong Wu, Harm J Bogaard, Lie Wang, Mengtao Li, Jun Yang   +9 more
wiley   +1 more source

Mucosal‐associated invariant T cells in rheumatic diseases.

Arthritis &Rheumatology, Accepted Article.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor (TCR) and restriction by the MHC class I‐related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines. Upon activation, MAIT cells rapidly produce pro‐inflammatory cytokines,
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Interstitial lung disease in a patient with anti-eIF2B antibodies-positive systemic sclerosis: A case report and literature review

Respiratory Medicine Case Reports
We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and, following a comprehensive physical examination, was ...
Naoya Aoshiba, Kazutoshi Toriyama, Shohei Yamashita, Nao Shioiri, Yuko Iwata, Tomonori Uruma, Shinji Abe, Kenji Tsushima   +7 more
doaj  

IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts

Biologics: Targets & Therapy, 2008
Mathieu C Tamby1, Amélie Servettaz1, Nicolas Tamas1, Joseph Reinbolt2, Frédéric Caux3, Olivier Meyer4, Yannick Allanore5, André Kahan5, Loïc Guillevin6, Luc Mouthon1,61Paris-Descartes University ...
Mathieu C Tamby, Amélie Servettaz, Nicolas Tamas, Joseph Reinbolt, Frédéric Caux, et al   +5 more
doaj  

Peripheral blood gene expression profiling shows prognostic significance for the course of interstitial lung disease in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective We used data from the placebo arm of the SENSCIS trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) with and without mycophenolate mofetil (MMF) treatment ...
Shervin Assassi, Christopher P. Denton, Matthias Zwick, Ramona Schmid, Carina Ittrich, Tobias Litzenburger, Sudha Visvanathan   +6 more
wiley   +1 more source